Desvenlafaxine Succinate
24 NDCs across 4 manufacturers|15 Generic,9 Brand
Desvenlafaxine Succinate is used to treat major depressive disorder, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Feb 29, 2008, and the first generic was approved Jun 29, 2015. FDA's Orange Book lists 31 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $67 million on Desvenlafaxine Succinate across 966,000 claims for 183,000 beneficiaries.
Desvenlafaxine Succinate is available as 24 NDCs from 4 manufacturers (15 generic, 9 brand), with NADAC prices from $0.40 to $13.97 per EA — the most expensive product costs about 35× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
24
15G / 9B
Manufacturers
4
competing in market
Price Spread
$0.40 – $13.97
per EA
7d Activity
avg +0.1% WoW · of 24 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
4 manufacturers producing DESVENLAFAXINE SUCCINATE
Frequently Asked Questions
What is Desvenlafaxine Succinate used to treat?
Desvenlafaxine Succinate is used to treat major depressive disorder, per the National Library of Medicine's MED-RT classification.
When did Desvenlafaxine Succinate become available as a generic?
FDA approved the first generic Desvenlafaxine Succinate (ANDA) on Jun 29, 2015. The Orange Book currently lists 31 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Desvenlafaxine Succinate?
In 2024, Medicare Part D spent $67 million on Desvenlafaxine Succinate across 966,000 claims for 183,000 beneficiaries.
How many Desvenlafaxine Succinate products are on the market?
The Desvenlafaxine Succinate drug market contains 24 NDCs from 4 manufacturers — 15 generic and 9 brand products.
What is the price range for Desvenlafaxine Succinate?
NADAC reference prices for Desvenlafaxine Succinate range from $0.3965 to $13.9730 per EA — the most expensive product costs about 35× the cheapest.
Is generic Desvenlafaxine Succinate cheaper than brand?
The average generic NADAC for Desvenlafaxine Succinate is $0.4037 per EA, versus $13.7499 for brand-labeled products — brand versions average about 34× the generic price.
Which manufacturers make Desvenlafaxine Succinate?
4 manufacturers list Desvenlafaxine Succinate in NADAC. Ranked by number of NDCs, the largest are Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (9), Breckenridge Pharmaceutical Inc. (8), Macleods Pharmaceuticals Limited (4), Lupin Pharmaceuticals Inc. (3).
How has the price of Desvenlafaxine Succinate changed recently?
Over the past 7 days, 15 Desvenlafaxine Succinate NDCs rose and 6 fell, with a market-wide average change of +0.1%.